The 2026 tau imaging news does not change the first steps of a memory workup. Primary-care patients still start with history, thinking tests, and blood-test triage, not a tau brain scan.
Tau PET is a brain scan that shows tau tangles linked to Alzheimer's. On Aug. 14, 2026, the FDA approved Lantheus TAUKLARIFY for adults with cognitive impairment evaluated for Alzheimer's, according to the Lantheus approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the FDA approve?
- Why doesn't stronger detection change screening?
- What works best in primary care?
- How should you read tau headlines?
What did the FDA approve?
TAUKLARIFY uses florquinitau F 18 to flag tau tangle pathology during an Alzheimer's evaluation. The label limits use to that purpose and warns that safety and effectiveness are not established for other tau diseases.
In two blinded read studies with five readers, NeurologyLive reported positive agreement of 68%-88% and negative agreement of 93%-99%, with strong reader consistency, in the NeurologyLive report. A positive or negative scan alone neither confirms nor rules out tau pathology.
Why doesn't stronger detection change screening?
In a May 2026 Lancet HEAD study that scanned the same people with two tracers, MK-6240 found tau more than twice as often as flortaucipir in unimpaired amyloid-positive people. It also separated Alzheimer's-related impairment better, according to the University of Pittsburgh summary.
That edge matters for staging and research, not for home screening. Early tau without amyloid or symptoms does not equal Alzheimer's dementia.
What works best in primary care?
At AAIC 2026, the Alzheimer's Association reported a Swedish study of 1,310 patients in which primary-care accuracy rose from 65% to 93% after a blood test for amyloid-beta and phosphorylated tau, in the AAIC release. That matched specialists at 94%.
Tau PET complements those tools rather than replacing them. Ask your primary-care clinician for steps in this order:.
- review memory concerns, medicines, sleep, mood, and daily function
- complete brief thinking tests plus a validated blood test for Alzheimer's markers
- use specialist referral to decide whether any brain scan fits
How should you read tau headlines?
Check who was scanned, what the scan was compared against, and whether symptoms were present. A result in unimpaired people has a different meaning than a result in people with memory loss.
Tau PET involves radiation, limited access, and uncertain coverage. Bring a symptom timeline, a medicine list, and your blood-test result if you seek a second opinion.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Primary Care Patients Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Primary Care Patients Can Avoid Overreading the Headline
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Primary Care Patients Can Avoid Overreading the Headline
